GlassScriptPhysician profile
Alison Zeik Smith
NPI 1992223739
$1,092.19
in general payments reported to CMS, 2019-2025
22 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.06 · 2022: $14.19 · 2023: $243 · 2024: $270 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $157.04 | 2025 | Lokelma, Farxiga |
| Genzyme Corporation | $154.42 | 2023 | |
| Mallinckrodt Hospital Products INC. | $90.46 | 2025 | Acthar |
| Calliditas Therapeutics US INC. | $84.88 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $72.39 | 2024-2025 | |
| Novo Nordisk INC | $68.67 | 2025 | Ozempic, Wegovy |
| Fresenius USA Marketing, INC. | $66.39 | 2024-2025 | Velphoro, Velphoro |
| Amgen INC. | $51.73 | 2024 | Tavneos |
| Janssen Biotech, INC. | $50.08 | 2023-2024 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $48.00 | 2021-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $38.58 | 2022-2023 | Ibsrela |
| Scpharmaceuticals INC. | $36.23 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.17 | 2024 | Relistor |
| Akebia Therapeutics INC | $20.48 | 2025 | Vafseo |
| Abbvie INC. | $17.84 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.76 | 2024 | |
| Lilly USA, LLC | $16.81 | 2024 | Jardiance |
| Gilead Sciences, INC. | $16.48 | 2023 | |
| Vifor Pharma, INC. | $16.36 | 2025 | Veltassa |
| Daiichi Sankyo INC. | $15.85 | 2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $15.08 | 2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $13.49 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.